Pure red cell aplasia

Blood

Volumn 128, Issue 21, 2016, Pages 2504-2509

  Means, Robert T ^a  

^a East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT ERYTHROPOIETIN;

BLOOD CELL COUNT; BONE MARROW; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; HUMAN; HUMAN PARVOVIRUS B19; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY; LYMPHOPROLIFERATIVE DISEASE; PARVOVIRUS INFECTION; PREGNANCY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; STEM CELL TRANSPLANTATION; THYMOMA; ANEMIA, DIAMOND-BLACKFAN; AUTOIMMUNE DISEASES; ERYTHEMA INFECTIOSUM; IMMUNOLOGY; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYELODYSPLASTIC SYNDROMES; PATHOLOGY;

ANEMIA, DIAMOND-BLACKFAN; AUTOIMMUNE DISEASES; ERYTHEMA INFECTIOSUM; HUMANS; LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYELODYSPLASTIC SYNDROMES; PARVOVIRUS B19, HUMAN;

EID: 85015007861     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-05-717140     Document Type: Review

References (44)

1. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142(4):505-514.
2. Ruggero D, Shimamura A. Marrow failure: a window into ribosome biology. Blood. 2014;124(18):2784-2792.
3. Fleming MD. The genetics of inherited sideroblastic anemias. Semin Hematol. 2002;39(4):270-281.
4. Means RT, Dessypris EN, Krantz SB. Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response. Br J Haematol. 1991;78:114-119.
5. Cerchione C, Catalano L, Cerciello G, et al. Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA). Ann Hematol. 2015;94(3):531-534.
6. van den Akker M, Dror Y, Odame I. Transient erythroblastopenia of childhood is an underdiagnosed and self-limiting disease. Acta Paediatr. 2014;103(7):e288-e294.
7. Dessypris EN, McKee CL Jr, Metzantonakis C, Teliacos M, Krantz SB. Red cell aplasia and chronic granulocytic leukaemia. Br J Haematol. 1981;48(2):217-225.
8. Frickhofen N, Chen ZJ, Young NS, Cohen BJ, Heimpel H, Abkowitz JL. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol. 1994;87(4):818-824.
9. Brown KE, Hibbs JR, Gallinella G, et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med. 1994;330(17):1192-1196.
10. Carson KR, Evens AM, Bennett CL, Luminari S. Clinical characteristics of erythropoietin-associated pure red cell aplasia. Best Pract Res Clin Haematol. 2005;18(3):467-472.
11. Bennett CL, Starko KM, Thomsen HS, et al. Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med. 2012;27(12):1697-1703.
12. Bernard C, Frih H, Pasquet F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev. 2016;15(1):82-92.
13. Dessypris EN. Pure red cell aplasia. Baltimore, MD: Johns Hopkins University Press; 1988.
14. Hirokawa M, Sawada K, Fujishima N, et al; PRCA Collaborative Study Group. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015;169(6):879-886.
15. Fujishima N, Sawada K, Hirokawa M, et al; PRCA Collaborative Study Group. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93(10):1555-1559.
16. Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014;89(11):1055-1062.
17. Masuda M, Teramura M, Matsuda A, et al. Clonal T cells of pure red-cell aplasia. Am J Hematol. 2005;79(4):332-333.
18. Hirokawa M, Sawada K, Fujishima N, et al. Acquired pure red cell aplasia associated with malignant lymphomas: a nationwide cohort study in Japan for the PRCA Collaborative Study Group. Am J Hematol. 2009;84(3):144-148.
19. Thompson DF, Gales MA. Drug-induced pure red cell aplasia. Pharmacotherapy. 1996;16(6):1002-1008.
20. Dessypris EN, Redline S, Harris JW, Krantz SB. Diphenylhydantoin-induced pure red cell aplasia. Blood. 1985;65(4):789-794.
21. Mariette X, Mitjavila MT, Moulinie JP, et al. Rifampicin-induced pure red cell aplasia. Am J Med. 1989;87(4):459-460.
22. Choudry MA, Moffett BK, Laber DA. Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome. Ann Hematol. 2007;86(4):233-237.
23. Aung FM, Lichtiger B, Bassett R, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160(6):798-805.
24. Au WY, Cheng VC, Wan TS, Ma SK. Myelodysplasia masquerading as parvovirus-related red cell aplasia with giant pronormoblasts. Ann Hematol. 2004;83(10):670-671.
25. Narla A, Vlachos A, Nathan DG. Diamond Blackfan anemia treatment: past, present, and future. Semin Hematol. 2011;48(2):117-123.
26. Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87(7):3000-3006.
27. Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87(11): 4831-4838.
28. Yoshida S, Konishi T, Nishizawa T, Yoshida Y. Effect of tacrolimus in a patient with pure red-cell aplasia. Clin Lab Haematol. 2005;27(1):67-69.
29. Auner HW, Wölfler A, Beham-Schmid C, Strunk D, Linkesch W, Sill H. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment. Br J Haematol. 2002;116(3):727-728.
30. D'Arena G, Vigliotti ML, Dell'Olio M, et al. Rituximab to treat chronic lymphoproliferative disorder-associated pure red cell aplasia. Eur J Haematol. 2009;82(3):235-239.
31. Mouthon L, Guillevin L, Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev. 2005;4(5):264-269.
32. Freund LG, Hippe E, Strandgaard S, Pelus LM, Erslev AJ. Complete remission in pure red cell aplasia after plasmapheresis. Scand J Haematol. 1985;35(3):315-318.
33. Zaentz DS, Krantz SB, Sears DA. Studies on pure red cell aplasia. VII. Presence of proerythroblasts and response to splenectomy: a case report. Blood. 1975;46(2):261-270.
34. Kochethu G, Baden HS, Jaworska E, Chang J, Chopra R. Reduced intensity conditioning bone marrow transplantation for pure red cell aplasia: successful outcome but difficult post transplant course. Bone Marrow Transplant. 2005;36(1):81-82.
35. Crabol Y, Terrier B, Rozenberg F, et al; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56(7):968-977.
36. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006;135(3):405-407.
37. Hirokawa M, Sawada K, Fujishima N, et al; PRCA Collaborative Study Group. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008;93(1):27-33.
38. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfus Med Hemother. 2016;43(1):3-12.
39. Macdougall IC, Casadevall N, Locatelli F, et al; PRIMS study group. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30(3):451-460.
40. Macdougall IC, Roger SD, de Francisco A, et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81(8):727-732.
41. Shimizu H, Saitoh T, Ota F, et al. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126(2):114-118.
42. Moussa M, Hassan MF. Newly diagnosed adult-onset Still's disease with pure red cell aplasia in pregnancy. Arch Gynecol Obstet. 2014;290(1):195-198.
43. Kashyap R, Pradhan M. Maternal and fetal outcome in pregnancy-associated pure red cell aplasia. J Obstet Gynaecol. 2010;30(7):733-734.
44. Lipton J, Glader B, Means RT. Red cell aplasia: acquired and congenital disorders. In: Greer JP, Arber DA, Glader BE, List A, Means RT, Paraskevas F, Rodgers GM, eds. Wintrobe's Clinical Hematology. 13th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:975-89.